(Credit: Shutterstock)
Crowded rheumatoid arthritis category gets JAK reality check, while TNF stalwarts continue to dominate: study
The FDA’s black box label slap on JAK rheumatoid arthritis brands last year hit where it hurt – in class reputation and prescriptions. But Pfizer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
